Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | PAM | P19021 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782819 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL29366771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10901771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2857061 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL28699910 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL355177 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL6266491 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10414846 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL353797 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL356145 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| EP-3863629-A1 | PRODRUGS OF CGRP ANTAGONISTS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | CALCRL, CALCA, CALCB | DGKA 2674/4885PAM 305/4885TSHR 1421/4885 |
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | DGKA 2674/4885PAM 305/4885TSHR 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.